Companies
(73)
AAC Clyde Space
ALM Equity
Alzinova
Arion Bank
Arlandastad Group
Ascelia Pharma
Bactiguard
Bergman & Beving
Besqab
BioPorto
Björn Borg
Bokusgruppen
Bonava
BTS Group
Byggmästaren
CAG Group
Calviks
Carasent
CDON
Clavister
Clemondo Group
eEducation Albert
Elanders
Elicera Therapeutics
Eolus
Ependion
EQL Pharma
Faron Pharmaceuticals
FluoGuide
Gentoo Media
GiG Software
HAKI Safety
HANZA
Iconovo
Idun Industrier
InfraCom
Initiator Pharma
Intervacc
ITAB Group
Kebni
Lifecare ASA
Lindex Group
Logistri
Lumi Education Group
Lytix Biopharma
Medivir
Mentice
Micro Systemation
MilDef Group
Net Insight
Nordic LEVEL Group
Orexo
Ortoma
OssDsign
Paxman
Pierce
PowerCell
Pricer
Qualisys
Relais Group
SaltX
Scanfil
Sensys Gatso Group
Sleep Cycle
Solar Foods
Spago Nanomedical
Svedbergs Group
Taaleri
Terranor
Vertiseit
Vivesto
W5 Solutions
Waystream
Sweden
Healthcare
FluoGuide is a Danish biotechnology company focused on developing its lead asset, FG001, a uPAR-targeting compound intended for fluorescence-guided surgery. Its current clinical-stage programmes include FG001 in high-grade glioma and oral head and neck cancer (both studies are in Phase II development). FG001 is administered intravenously hours before a patient’s surgery and binds to uPAR-expressing cancer cells. During surgery, a standard near-infrared imaging system excites the fluorophore, causing tumour tissue to fluoresce in real time and enabling surgeons to distinguish malignant tissue from surrounding healthy tissue.
Key industry drivers
Rising cancer incidence and surgical volumes.
Increasing fluorescence-guided surgery.
Demand for improved surgical precision.
Industry outlook
Broader adoption of targeted imaging agents.
Expansion of fluorescence-guided surgery across tumours.
Expanding reimbursement and clinical guideline support.
Key peers
Photocure, SBI Holdings, On Target Laboratories, SurgiMab, Lumicell, Vergent Bioscience.
Name
Capital
Votes
Life Science ApS
22.1 %
22.1 %
Linc AB
5.0 %
5.0 %
AL Sydbank A/S
5.0 %
5.0 %
3F
5.0 %
5.0 %
Fødevareforbundet NNF
5.0 %
5.0 %
Dansk Metal
5.0 %
5.0 %
About DNB Carnegie Access
DNB Carnegie Access aim is to connect listed companies with the capital markets. Through top ranked public equity research and broad distribution via written reports, seminars, video, and podcasts, we increase visibility and investor understanding for small- and medium-sized companies, both among institutional and private investors.
Along with corporate finance, market making and certified advisory we provide a complete product offering to our clients.
Private Banking
Tailored wealth management. Your financial future, personalized.
Montrose
A digital investment platform designed for passionate investors.
DNB Carnegie
Leading Nordic investment bank and wealth management.
© Copyright DNB Carnegie Investment Bank AB